CRMD
$4.73
Cormedix
($.26)
(5.21%)
CRMD
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.22)
Revenue:  $0.04 Mil
Tuesday
Feb 8
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CRMD reports earnings?
Beat
Meet
Miss

Where is CRMD's stock price going from here?
Up
Flat
Down
Stock chart of CRMD
Analysts
Summary of analysts' recommendations for CRMD
Score
Grade
Pivots
Resistance
$5.25
$5.12
$4.92

$4.79

Support
$4.59
$4.46
$4.26
Tweet
Growth
Description
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrog
Peers
Vertex PharmaceuticalsUltragenyx PharmaceuticalRegeneron PharmaceuticalsBioMarin PharmaceuticalMerck & Co.ZoetisEli LillyBristol-Myers SquibbPfizerInterCept